This demonstration project will assess the acceptability and feasibility of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV prevention package in community-based clinics in West Africa. An interventional, open label, multidisciplinary and multicentre cohort study will be performed in Burkina Faso, Côte d'Ivoire, Mali, and Togo. All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (daily or on-demand, according the participant's choice), immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of MSM under PrEP among eligible HIV-seronegative participants
Timeframe: 3 years
Percentage of MSM using daily and/ord on-demand PrEP
Timeframe: 3 years
Number of MSM followed after 3 years compared to the number of MSM included (retention in the program)
Timeframe: 3 years
Percentage of adherence reported by MSM
Timeframe: 3 years
Counting of TDF/FTC tablets
Timeframe: 3 years
Plasma concentrations of TDF and FTC
Timeframe: 3 years
Percentage of HIV tests performed
Timeframe: 3 years
Clinical and biological adverse events related to TDF and FTC
Timeframe: 3 years
Frequency of condomless anal intercourse
Timeframe: 3 years
Frequency of sexual intercourse associated with alcohol and/or drug use
Timeframe: 3 years
Incidence rate of STIs
Timeframe: 3 years
Incidence rate of HIV infection
Timeframe: 3 years
Percentage of TDF/FTC resistance among MSM newly infected by HIV
Timeframe: 3 years
Total cost of the intervention over the study period and in the long term
Timeframe: 3 years
Incremental cost-effectiveness ratio of the intervention (versus no intervention) over the study period and in the long term
Timeframe: 3 years
Conditions of TDF/FTC price and of effectiveness for the intervention to be cost-effective in the study countries
Timeframe: 3 years